Industry news

• California Assembly Passes Bill on Biosimilar Drug Use

  27 August 2013 Mark Melnicoe, Bloomberg

  Pharmaceutical makers won approval from the California Assembly to restrict generic versions of drugs isolated from natural sources, such as vaccines, known as biosimilars, once they become available in the U.S.

• Russian scientists develop revolutionary drugs for cancer, HIV and tuberculosis

  13 August 2013 Marchmont Innovation News

  Russian scientists are developing three types of next gen vaccines that might evolve into the revolutionary drugs for cancer, HIV and tuberculosis, Informing.ru  reported , citing Vladimir Uiba, the director of Russia’s Federal Agency for Medicine and Biology. 
   

• How to invest in Russian technoparks

  08 August 2013 Daniil Zhelobanov, Russia Beyonds the Headlines

  Technoparks can be a boon for both foreign investors willing to set up their business in Russia.

• Venture capital warms to European biotechs

  08 August 2013 Caroline Copley, Reuters

  While a wave of stock market enthusiasm in the United States for biotech company flotations has yet to cross the Atlantic, venture capital appetite for promising European companies is returning.

• Amount of private investments in Skolkovo can reach 367B RUB

  06 August 2013 Venture News

  According to the Chief of the Fund Skolkovo Viktor Vekselberg, till the year 2020 the amount of private investments in the project of innovation center can reach 367B RUB, and after the year 2025 the budget funds for the project will not be required.
   

• Russian government to regulate prices for essential drugs

  02 August 2013 The Pharma Letter

  The Russian government is considering tightening its pricing policy in the domestic market for essential drugs, with the aim of preventing unreasonable price rises for them in the future. According to the Russian Ministry of Health, it is planned that ceiling prices for foreign essential drugs sold in Russia will not exceed the average European prices for the same types of drugs.

• ReVision Optics and NovaMedica sign commercial agreement to market and distribute Raindrop vision correction technology in Russia

  31 July 2013

  

  NovaMedica, a Russian pharmaceutical and medical device company, and ReVision Optics, Inc. the U.S. developer of the innovative refractive surgery solution against presbyopia Raindrop™ Near Vision Corneal Inlay, have signed an agreement to commercialize this technology in Russia.

• J&J buys into ReVision Optics' $55M financing round

  30 July 2013 Mark Hollmer, FierceMedicalDevices

  

  ReVision Optics attracted an impressive $55 million in new equity financing from the likes of Johnson & Johnson ($JNJ) and a Russian investor group--a massive cash infusion that will advance its hydrogel eye implant designed to help reduce the need for reading glasses.

• New Russian company to build $85M plant

  30 July 2013 Eric Palmer, FiercePharmaManufacturing

  

  NovaMedica was formed out of Domain Associates' partnership with RUSNANO.

• $85m Plant Demonstrates Russia's Commitment to Pharma 2020, says NovaMedica

  29 July 2013 Dan Stanton, In-Pharma Technologist.com

  

  NovaMedica and the Russian Government are to build an $85m (€64m) facility as part of a joint venture encouraging local manufacturing, the company says.